AIRLINK 73.18 Increased By ▲ 0.38 (0.52%)
BOP 5.00 Decreased By ▼ -0.06 (-1.19%)
CNERGY 4.37 Increased By ▲ 0.04 (0.92%)
DFML 29.95 Decreased By ▼ -0.57 (-1.87%)
DGKC 91.39 Increased By ▲ 5.44 (6.33%)
FCCL 23.15 Increased By ▲ 0.80 (3.58%)
FFBL 33.50 Increased By ▲ 0.28 (0.84%)
FFL 9.92 Increased By ▲ 0.14 (1.43%)
GGL 10.35 Decreased By ▼ -0.05 (-0.48%)
HBL 113.01 Decreased By ▼ -0.61 (-0.54%)
HUBC 136.28 Increased By ▲ 0.08 (0.06%)
HUMNL 9.60 Decreased By ▼ -0.43 (-4.29%)
KEL 4.78 Increased By ▲ 0.12 (2.58%)
KOSM 4.72 Increased By ▲ 0.32 (7.27%)
MLCF 39.89 Increased By ▲ 1.54 (4.02%)
OGDC 133.90 Increased By ▲ 0.50 (0.37%)
PAEL 28.85 Increased By ▲ 1.45 (5.29%)
PIAA 25.00 Increased By ▲ 0.24 (0.97%)
PIBTL 6.94 Increased By ▲ 0.39 (5.95%)
PPL 122.40 Increased By ▲ 1.19 (0.98%)
PRL 27.40 Increased By ▲ 0.25 (0.92%)
PTC 14.80 Increased By ▲ 0.91 (6.55%)
SEARL 60.40 No Change ▼ 0.00 (0%)
SNGP 70.29 Increased By ▲ 1.76 (2.57%)
SSGC 10.42 Increased By ▲ 0.09 (0.87%)
TELE 8.85 Decreased By ▼ -0.20 (-2.21%)
TPLP 11.32 Increased By ▲ 0.06 (0.53%)
TRG 66.57 Increased By ▲ 0.87 (1.32%)
UNITY 25.20 Decreased By ▼ -0.05 (-0.2%)
WTL 1.55 Increased By ▲ 0.05 (3.33%)
BR100 7,676 Increased By 42.9 (0.56%)
BR30 25,471 Increased By 298.6 (1.19%)
KSE100 73,086 Increased By 427.5 (0.59%)
KSE30 23,427 Increased By 44.5 (0.19%)

imageTOKYO: Japan's top drugmaker on Friday reported an annual loss for the first time in its history after agreeing to pay $2.4 billion to settle US lawsuits over cancer claims regarding its Actos diabetes drug.

Osaka-based Takeda($1.22 billion) as it took huge charges to settle the claims, reversing a year earlier profit and marking its only loss since becoming a publicly listed company in 1949.

But revenue grew 5.1 percent to 1.78 trillion yen, helped by a weaker yen as well as higher-than expected sales of gout and myeloma cancer drugs. The firm said it expects to swing to a 68 billion yen profit this year.

Takeda warned last month it would report a big loss after announcing the US settlement agreement, which resolves lawsuits representing some 8,000 people who used the treatment for Type 2 diabetes beginning in the late 1990s.

They claimed the company did not warn them that it increases the risks of cancer.

Takeda said it agreed to pay out $2.37 billion if 95 percent of the litigants agree to the deal, rising to $2.4 billion if the number rises to 97 percent or more.

The company has nevertheless said it believes the claims of the litigants "are without merit and does not admit liability".

Actos continues to be available in the United States, Japan and other countries.

"The settlement will reduce financial uncertainties for the company and provides a significant degree of assurance toward resolving a high percentage of the Actos product liability claims," it said last month.

Last year a federal jury in the state of Louisiana ordered Takeda and US-based Eli Lilly & Co. to pay a combined $9.0 billion in punitive damages to a patient who said Actos had caused his bladder cancer.

A judge later slashed the payout to $36.8 million.

Eli Lilly was Takeda's US marketing and sales partner until 2006, with the US firm keeping the rights to sell Actos in parts of Asia and Europe, as well as in Canada and Mexico.

Copyright AFP (Agence France-Presse), 2015

Comments

Comments are closed.